Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Drygin

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Investigational New Drugs|February 24, 2022
The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcomaChang-Won Kang, Katherine M Hannan, Anneke C Blackburn, et al.
Biochemical and Biophysical Research Communications|October 27, 2011
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancerDenis Drygin, Caroline B Ho, Mayuko Omori, et al.
Biomedicines|May 16, 2023
Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment StudiesChang-Won Kang, Anneke C Blackburn, Amos Hong Pheng Loh, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2011
7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activityFabrice Pierre, Eric Stefan, Anne-Sophie Nédellec, et al.
Cancer Letters|March 6, 2012
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cellsJoshua Bliesath, Nanni Huser, Mayuko Omori, et al.
Cancer Research|December 17, 2010
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacyAdam Siddiqui-Jain, Denis Drygin, Nicole Streiner, et al.
Cancer Research|September 10, 2009
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesisDenis Drygin, Adam Siddiqui-Jain, Sean O'Brien, et al.
Oncotarget|February 13, 2016
Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cellsHagen Kulbe, Francesco Iorio, Probir Chakravarty, et al.
Bioorganic & Medicinal Chemistry Letters|December 16, 2011
Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogsMustapha Haddach, Fabrice Pierre, Collin F Regan, et al.
Molecular Cancer Therapeutics|January 24, 2012
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapyAdam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Investigational New Drugs|February 24, 2022
The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcomaChang-Won Kang, Katherine M Hannan, Anneke C Blackburn, et al.
Biochemical and Biophysical Research Communications|October 27, 2011
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancerDenis Drygin, Caroline B Ho, Mayuko Omori, et al.
Biomedicines|May 16, 2023
Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment StudiesChang-Won Kang, Anneke C Blackburn, Amos Hong Pheng Loh, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2011
7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activityFabrice Pierre, Eric Stefan, Anne-Sophie Nédellec, et al.
Cancer Letters|March 6, 2012
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cellsJoshua Bliesath, Nanni Huser, Mayuko Omori, et al.
Cancer Research|December 17, 2010
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacyAdam Siddiqui-Jain, Denis Drygin, Nicole Streiner, et al.
Cancer Research|September 10, 2009
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesisDenis Drygin, Adam Siddiqui-Jain, Sean O'Brien, et al.
Oncotarget|February 13, 2016
Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cellsHagen Kulbe, Francesco Iorio, Probir Chakravarty, et al.
Bioorganic & Medicinal Chemistry Letters|December 16, 2011
Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogsMustapha Haddach, Fabrice Pierre, Collin F Regan, et al.
Molecular Cancer Therapeutics|January 24, 2012
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapyAdam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, et al.
Pageof 4